Abstract:The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise globally. Liver transplant (LT) recipients continue to be older and have inherently more comorbidities. Among these, cardiac disease is one of the three main causes of morbidity and mortality after LT. Several reasons exist including the high prevalence of associated risk factors, which can also be attributed to the rise in the proportion of patients undergoing LT for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, as people age, the prevalence of now treatable cardiac conditions, including coronary artery disease (CAD), cardiomyopathies, significant valvular heart disease, pulmonary hypertension, and arrhythmias rises, making the need to treat these conditions critical to optimize outcomes. There is an emerging body of literature regarding CAD screening in patients with ESLD, however, there is a paucity of strong evidence to support the guidance regarding the management of cardiac conditions in the pre-LT and perioperative settings. This has resulted in significant variations in assessment strategies and clinical management of cardiac disease in LT candidates between transplant centres, which impacts LT candidacy based on a transplant centre's risk tolerance and comfort level for caring for patients with concomitant cardiac disease. Performing a comprehensive assessment and understanding the potential approaches to the management of ESLD patients with cardiac conditions may increase the acceptance of patients, who appear too complex, but rather require extra evaluation and may be reasonable candidates for LT. The unique physiology of ESLD can profoundly influence preoperative assessment, perioperative management, and outcomes associated with underlying cardiac pathology, and requires a thoughtful multidisciplinary approach. The strategies proposed in this manuscript attempt to review the latest expert experience and opinions and provide guidance to practicing clinicians who assess and treat patients being considered for LT. These topics also highlight the gaps that exist in the comprehensive care of LT patients and the need for future investigations in this field. Liver transplant candidates require a detailed cardiovascular assessment, involving a multidisciplinary approach, which incorporates evaluation of traditional and ESLD factors as well as evaluation for cardiac conditions including coronary artery disease, cardiomyopathies, and rhythm disturbances. Liver disease induces systemic hemodynamic changes including portal hypertension, increased cardiac output, and vascular resistance alterations, predisposing candidates to cardiovascular complications. Thorough cardiovascular evaluation may involve non-invasive tests (electrocardiography, echocardiography, cardiac biomarkers, coronary artery calcium score, stress testing) and invasive assessments (coronary angiography) to stratify risk and guide management decisions. Optimal management should involve lifestyle modifications, pharmacotherapy, revascularization for high-risk patients after discussion with a heart team, review of the immunosuppression regimen, and preoperative optimization. Successful cardiovascular management in liver transplant candidates improves perioperative outcomes and reduces postoperative complications. CNI, calcineurin inhibitor; CSA, cyclosporine; ECG, electrocardiogram; ESLD, end-stage liver disease; MELD, model for end-stage liver disease; MASH, metabolic dysfunction-associated steatohepatitis; Tac, tacrolimus.

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

Expert consensus on the use of mycophenolic acid in Chinese liver and kidney transplant recipients(2023 edition)

Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: the impact of pre-existing diabetes mellitus.

Chinese expert consensus on clinical application of inhibitors of mammalian target of rapamycin in liver transplant recipients(2023 edition)

Navigating Immune Cell Immunometabolism after Liver Transplantation

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Extrahepatic Organs in the Development of Non-Alcoholic Fatty Liver Disease in Liver Transplant Patients.

Expert Consensus on Perioperative Management of Liver Transplantation in Adults with Acute-on-chronic Liver Failure

Post-Transplant Diabetes Mellitus in Liver Transplantation: Hangzhou Experience

The interaction of T2DM and BMI with NASH in recipients of liver transplants: an SRTR database analysis

Research progress on risk factors and management measures of metabolic complications after liver transplantation

Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long‐Term Survival

Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus

Cardiovascular disease assessment and management in liver transplantation

Metabolic Syndrome in Liver Transplant Recipients:Prevalence and Risk Factors

Effect of Immunosuppressive Regimens on Metabolic Dysfunction-associated Fatty Liver Disease Following Liver Transplantation

Meta-Analysis of the Effects of Exercise Training on Markers of Metabolic Syndrome in Solid Organ Transplant Recipients.

Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)

Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma

The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients

Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events.